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Abstract 
Vibrio vulnificus biotype 1, a causative agent of fatal septicemia or wound infection 
in humans, is known to produce a toxic metalloprotease as an important virulence 
determinant. V. vulnificus biotype 2 (serovar E), a primary eel pathogen, was found to 
elaborate an extracellular metalloprotease that was indistinguishable from that of 
biotype 1. The potential of V. vulnificus biotype 1 for production of the metalloprotease 
was compared with biotype 2 and other human non-pathogenic Vibrio species (V. 
anguillarum and V. proteolyticus). When cultivated at 25 oC in tryptone-yeast extract 
broth supplemented with 0.9 % NaCl, all bacteria multiplied sufficiently and secreted 
significant amounts of the metalloprotease. However, at 37 oC with 0.9 % NaCl, V. 
anguillarum neither grew nor produced the metalloprotease. In human serum, only V. 
vulnificus biotype 1 revealed a steady multiplication accompanied with production of 
the extracellular metalloprotease. This prominent ability of biotype 1 in growth and 
protease production may contribute to cause serious systemic diseases in humans. 
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Introduction 
Vibrio vulnificus biotype 1 is a human pathogen causing fatal septicemia or wound 
infection, and the infection is characterized by formation of hemorrhagic and 
edematous lesions on the limbs [1]. This bacterium produces a 45-kDa 
thermolysin-like metalloprotease (V. vulnificus protease [VVP]) as an important 
virulence determinant, which increases vascular permeability and causes serious 
hemorrhagic damage [2,3]. V. vulnificus biotype 2 that is also named as serovar E [4] 
is a primary causative agent of epizooticus in eel farms [5,6], while it has isolated 
occasionally from human clinical sources [7]. Our preliminary experiments using 
partially purified preparations indicated that an extracellular protease produced by 
biotype 2 might be indistinguishable from VVP. In spite of their being avirulent to 
humans, other vibrios such as V. anguillarum [8,9] and V. proteolyticus [10] also 
produce closely related metalloproteases those exhibit 70-80 % identities in the 
primary structures and have comparable biological activities. Additionally, these 
proteolytic enzymes are neutralized with the antibody against VVP [11]. 
In various microorganisms, production of extracellular proteases, as well as other 
factors, is coordinated by the quorum sensing or cell density-dependent regulation 
system [12,13]. Two kinds of quorum-sensing systems have been reported in V. 
anguillarum. One system is operated by a small substance, 
N-(3-oxodecanoyl)-L-homoserine lactone [14], while another system is linked to a 
substance related to V. harveyi autoinducer 2 (AI-2) [15]. In V. vulnificus biotype 1, 
VVP production is positively regulated by the system dependent on the AI-2-like 
substance [16,17,18]. Namely, expression of the vvp gene is augmented at stationary 
growth phase because of sufficient bacterial multiplication followed by accumulation 
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of the AI-2-like substance. 
The present study showed that V. vulnificus biotype 1 was able to multiply in 
human plasma. Therefore, although both biotypes have equal capability of producing 
toxic metalloproteases in vitro, only biotype 1 is capable of growing and therefore 
secreting the metalloprotease in humans. 
 
Results and Discussion 
Extracellular protease produced by biotype 2 
For purification of a metalloprotease (E86 protease), the supernatant of the 24-h 
culture of V. vulnificus E86, a biotype 2 strain, was fractionated by ammonium sulfate 
precipitation. Thereafter, the preparation was subjected to gel filtration on a HiLoad 
26/60 Sephacryl S-200 HR column and hydrophobic interaction chromatography on a 
HiLoad 10/2 Phenyl Sepharose column. The final preparation thus obtained revealed 
homogeneity on SDS-PAGE. Namely, in the presence or absence of a reducing agent, 
a single protein band with a molecular mass of 45-kDa, the same size as VVP from 
biotype 1, was formed. 
The purified E86 protease (1.0 nmol) showed sufficient proteolytic activities toward 
both azocasein (490 PU) and elastin-Congo red (95 EU), which were very close to 
those of recombinant VVP (520 PU and 89 EU) used as a positive control. Likewise 
VVP [2,3], E86 protease was inactivated by incubation with phosphoramidon or zincov, 
the competitive peptide inhibitor for thermolysin-like zinc metalloproteases. 
Additionally, in the immunodiffusion test using the IgG antibody against VVP, E86 
protease formed a clear precipitation line fused completely with the line to VVP. When 
injected into a guinea pig skin, it showed the comparable permeability-enhancing and 
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hemorrhagic activity (data not shown). 
In order to study genetic identity, PCR amplification using primers for the vvp gene 
was carried out. As shown in Fig. 1, the 668-bp product was detected from V. 
vulnificus E86, as well as biotype 1 strains. Additionally, a total of 12 V. vulnificus 
strains including 5 strains in the biotype 2 were tested for PCR amplification. The 
results revealed that all strains produced the same size amplicon (data not shown). 
However, 6 strains from other Vibrio species including V. anguillarum and V. 
proteolyticus did not produce the amplicon (data not shown). 
Taken together, it may be concluded that an extracellular metalloprotease 
elaborated by V. vulnificus biotype 2 is closely related to or identical with VVP 
produced by biotype1. 
 
Bacterial growth and protease production in a complex medium 
When cultivated at 25 or 37 oC in TYE broth (0.5 % tryptone, 0.25 % yeast extract, 
25 mM K2HPO4 [pH 7.5]) supplemented with 0.9 or 3.0 % NaCl, V. vulnificus L-180 (a 
biotypes 1 strain), V. vulnificus E86, and V. proteolyticus ATCC 15338 showed 
sufficient growth under all experimental conditions (Fig. 2). However, V. anguillarum 
FY-8701 multiplied very poorly in the broth containing 0.9 % NaCl when cultivated at 
37 oC (Fig. 2). Temperature and/or salinity were found to modulate protease 
production (Fig. 3). V. vulnificus L-180 could produce sufficient amounts of the 
protease at 25 oC, however, much less protease was produced at 37 oC. Protease 
production by V. vulnificus E86 was also regulated, but less effectively. By contrast, V. 
proteolyticus ATCC 15338 could elaborate the protease independent of the cultivation 
conditions. On the other hand, V. anguillarum FY-8701 produced a little amounts of 
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the protease even when cultured at 25 oC. The extracelluar protease secreted by 
each vibrio was completely neutralized with the antibody against VVP, indicating the 
thermolysin-like metalloprotease is a single protease secreted. 
It should be noted that, all vibrios elaborated significant amounts of the 
metalloprotease only at the stationary phase. These findings strongly suggest that 
protease production correlates to the bacterial cell density. In fact, the 
quorum-sensing system has been shown to regulate the protease production [14, 
15,16,17,18]. However, in spite of enough multiplication, V. vulnificus and V. 
anguillarum showed decreased protease production at 37 oC. Therefore, efficiency of 
the quorum-sensing system is thought to be dependent on the cultivation conditions. 
Our preliminary experiments indicated that secretion of the AI-2-like substance by V. 
vulnificus biotype 1 was detected at mid-logarithmic phase and increased several 
times at stationary phase when cultivated at 25 oC, while its secretion reached 
maximum around mid-logarithmic phase at 37 oC. Indeed, in Gram-negative bacteria 
including Escherichia coli, Salmonella enterica serovar Typhimurium and Helicobacter 
pylori, production of the signal substance operating the quorum-sensing system has 
been documented to be regulated by metabolic or environmental conditions such as 
growth phase, pH, and osmolarity [19,20].  
However, the quorum-sensing system is not a sole regulation mechanism in V. 
vulnificus biotype 1. Jeong et al. [21] reported positive regulation of VVP production by 
cAMP-CRP (cAMP receptor protein) at 30 oC. We also found that the addition of 0.5 % 
glucose caused remarkable reduction of the extracellular protease activity when V. 
vulnificus L-180 was cultivated at 25 oC, suggesting contribution of the cAMP-CRP 
regulation system (data not shown). 
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Bacterial growth and protease production in human serum 
Each bacterial strain was inoculated into heat-treated 50 % human serum and 
incubated at 37 oC with shaking. V. vulnificus L-180 showed significant growth, 
however, others including V. vulnificus E86 could not multiply even when incubated 
for 28 h (Fig. 4A). The cell-free serum sample was collected periodically, and dialyzed 
against 60 % acetone followed by 0.9 % NaCl to regenerate the proteolytic activity 
blocked by α-macroglobulin [22], a broad-spectrum protease inhibitor in human 
plasma [23]. The sample obtained at 12-h incubation showed a very low, but 
significant proteolytic activity, while the sample from 28-h incubation revealed much 
higher proteolytic activity (Fig. 4B). Since the specific antibody neutralized the activity 
almost perfectly, the biotype 1 strain was confirmed to produce VVP during incubation 
in human serum. 
Heat-inactivated human serum is known to restrict bacterial growth because of the 
absence of essential nutrients including free iron [24,25]. However, the infection 
caused by V. vulnificus biotype 1 is often associated with patients who have diseases 
predisposing them to iron overload [26,27]. The inability of biotype 1 to multiply in 
human serum in the presence of ethylene diamine di(o-hydroxyphenyl acetic acid), an 
iron chelator used for removal of free iron, has been documented [28,29]. However, 
present study clearly indicated that expression of the iron-assimilating system 
resulting in sufficient bacterial growth was triggered in human serum if the iron 
chelator is absent. V. vulnificus biotype 1 synthesizes a phenolate-type siderophore 
named vulnibactin [30], which can sequester transferrin-bound iron for growth in 
human serum. Biosca et al. [31] have reported that a siderophore produced by biotype 
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2 was a hydoxamate-type, not a phenolate-type. The results in Fig.4 may suggest the 
inability of the hydroxamate-type siderophore to remove iron from human transferrin. 
Although it is essential for iron-assimilation, vulnibactin can remove iron only from 
transferrin digested by VVP [32]. The present study, in which VVP production was 
observed even at early growth phase, may support our previous conclusion. 
VVP-dependence of iron-assimilation in human serum was confirmed by the following 
experiment. When the VVP-deficient mutant [33] was inoculated into human serum, 
neither bacterial growth nor VVP production was observed (data not shown). 
The virulent potential of V. vulnificus biotype 2 to mice has been reported to be 
equal to that of biotype1 [34]. We recently found that mouse serum, as well as rabbit 
serum [28], contained much free iron and allowed enough bacterial growth [29]. As 
shown in Fig. 5, both biotypes revealed sufficient multiplication and protease 
production when incubated in 50 % rabbit serum. This result suggests that V. 
vulnificus biotype 2 also cause systemic infections in individuals whose serum iron 
levels are extremely increased. Indeed, a few strains isolated from human clinical 
sources have been identified to be biotype 2 [4,7]. In contrast to V. vulnificus, V. 
anguillarum and V. proteolyticus could not secrete a protease because of negligible 
multiplication, indicating deficiency of the virulence determinant(s) other than the 
iron-assimilating system. 
Mice were used for evaluation of the virulent potential of V. vulnificus biotype 1. 
Using this experimental animal, VVP-null mutants constructed by disruption of the vvp 
gene revealed full virulence [35,36]. However, these findings may not lead the 
conclusion that VVP is not a virulence determinant because biotype 1 administrated to 
mouse is possible to grow sufficiently without production of VVP.  
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The bacterial pathogenicity is determined by invasiveness, resistance to host 
defense systems, production of virulence factor(s) and others. So far, no virulence 
determinant specific to V. vulnificus biotype 1 is not known. For instance, both 
biotypes 1 and 2 can express capsule, which resists to the vibriocidal action of human 
serum, and can produce cytolytic exotoxin, which may support bacterial invasion. 
However, in the present study, biotype 1 showed the distinguished and excellent 
potential for multiplication and protease production in human serum. This may be one 
of the important prominences to cause drastic human diseases, such as septicemia 
accompanied with serious skin lesions. 
 
Materials and Methods 
Protease preparations 
V. vulnificus E86 provided kindly by Dr. C. Amaro (Universidad de Valencia, Spain) 
was cultivated in tryptic soy broth (Difco Laboratories, Detroit, Mich., USA) containing 
1.5 % NaCl at 25 oC for 24 h with shaking (120 cycles/min). After cultivation, the 
culture supernatant was collected by centrifugation at 7,000 x g for 40 min, and 
ammonium sulfate was added to 60 % saturation. The resulting precipitate was 
collected, dissolved in distilled water, and applied to a HiLoad 26/60 Sephacryl S-200 
HR column (Amersham Biosciences, Piscataway, N.J., USA) equilibrated with 20 mM 
Tris-HCl buffer containing 1 mM CaCl2, 0.9 % NaCl and 0.02 % NaN3 (pH 7.4). The 
fractions showed the high proteolytic activity toward azocasein (Sigma-Aldrich, St. 
Louis, Mo., USA) were collected and dialyzed against 20 mM Tris-HCl buffer 
supplemented with 1 mM CaCl2 (pH 7.4). This dialyzed preparation was loaded on a 
HiLoad 10/2 Phenyl Sepharose column (Amersham Biosciences) equilibrated with the 
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same buffer. The bound protease was eluted by a linear gradient with 0 to 30 % 
ethylene glycol in the same buffer. 
The recombinant VVP was isolated from the periplasmic fraction of a transformant, 
Escherichia coli DH5α/pVVP7-1, by ammonium sulfate precipitation followed by 
column chromatography on a HiLoad 16/10 Phenyl Sepharose column (Amersham 
Biosciences) as described [37]. 
 
Bacterial growth experiments 
V. vulnificus L-180 isolated from human blood [38], V. vulnificus E86 from a 
diseased eel [4], V. anguillarum FY-8701 from a diseased turbot, and V. proteolyticus 
ATCC 15338 were cultivated in TYE broth supplemented with 2.0 % NaCl at 25 oC for 
overnight. After cultivation, the bacterial cells were harvested, rinsed twice with 0.9 % 
NaCl, and inoculated into 2 ml of TYE broth containing 0.9 or 3.0 % NaCl at a 
cell-density of 1 x 107 CFU/ml. Thereafter, the bacteria were cultured at 25 or 37 oC 
with shaking, and growth was periodically monitored by measuring absorbance at 600 
nm. 
For studies on bacterial growth in mammalian serum, rabbit or human serum 
(Chemicon, Temecula, Calif., USA) was heat-treated at 56 oC for 30 min, and the 
precipitate was removed by centrifugation at 12,000 x g for 30 min. The heat-treated 
serum was diluted two-fold with 0.9 % NaCl and sterilized by membrane filtration 
(pore size 0.22 μm). The bacterial cells precultured at 25 oC in TYE broth containing 
2.0 % NaCl were inoculated into 2 ml of the diluted serum at a cell-density of 1 x 107 
CFU/ml, and incubated at 37 oC with shaking. 
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SDS-PAGE 
To inactivate the protease, the sample was mixed with an equal volume of 20 % 
trichloroacetic acid, and the resulting precipitate was collected, rinsed twice with 
ethanol, and treated with 1 % SDS at 100 oC for 3 min in the presence or absence of 
5 % 2-mercaptoethanol. Electrophoresis was performed on a PhastSystem with a 
PhastGel Gradient 10-15 % gel (Amersham Biosciences) according to the 
manufacturer’s manual. After electrophoresis, the gel was stained with 0.5 % 
Coomassie brilliant blue R-250 and destained with 25 % ethanol-8 % acetic acid. 
 
Assay of the proteolytic activity 
The protease activity toward azocasein was assayed as described previously [38]. 
The sample was allowed to act at 30 oC for an appropriate period on 1.0 mg of 
azocasein in 0.6 ml of 50 mM Tris-HCl buffer (pH 8.0), and the reaction was stopped 
by addition of 1.4 ml of 5 % trichloroacetic acid. After centrifugation at 1,000 x g for 5 
min, an aliquot of the supernatant was withdrawn and mixed with an equal volume of 
0.5 M NaOH. Thereafter, the increase of absorbance at 440 nm was measured. One 
protease unit (PU) was defined as the amount of the sample hydrolyzing 1 μg of the 
substrate in 1 min. 
The elastase activity toward elastin-Congo red was determined by the method of 
Kothary and Kreger [39]. The sample was allowed to act at 30 oC for 3 h on 2.0 mg of 
elastin-Congo red in 0.2 ml of 50 mM Tris-HCl buffer (pH 8.0), and the reaction was 
stopped by addition of 1.0 ml of the ice-cold buffer. Thereafter, the increase of 
absorbance at 495 nm was measured. One elastase unit (EU) was defined as the 
amount of the sample hydrolyzing 1 μg of the substrate in 1 min. 
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PCR for the vvp gene 
Genomic DNA was prepared by the miniprep procedure from the bacterial cells 
cultivated in Luria-Bertani broth containing 1.0 % NaCl. The primers for amplification 
of the segment of the vvp gene (5’-CATGTGTTCTCTTCCAGTCAC-3’, sense primer, 
and 5’-TCACCACGCTCTTTTCCATCG-3’, antisense primer) corresponding to bases 
at 653 to 673 and at 1300 to 1320, respectively, were designed from the DNA 
sequence of the vvp gene of V. vulnificus L-180 submitted to the DDBJ, EMBL, and 
GeneBank databases (accession number AB084580). After denaturation at 95 oC for 
2 min, the amplification reactions were performed for 30 cycles as follows; 30-sec 
denaturation at 95 oC, 30-sec annealing at 52 oC, and 1-min extension at 72 oC. The 
PCR products were elctrophoresed on a 1.2 % agarose gel and visualized by staining 
with ethidium bromide. 
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Figure legends 
Fig. 1. Agarose gel electrophoresis of PCR products obtained with primers for the 
vvp gene. Lane M, molecular size markers; lanes 1-3, V. vulnificus biotype 1 strains 
(L-180, 332, and E-4); lane 4, V. vulnificus biotype 2 strain E86. 
 
Fig. 2. Growth of vibrios in TYE broth. The bacterial cells (2 x 107 CFU) inoculated 
into 2 ml of TYE broth containing 0.9 or 3.0 % NaCl were cultivated at 25 or 37 oC with 
shaking, and growth (A600) was measured periodically. 
 
Fig. 3. Protease production by vibrios in TYE broth. The culture supernatant was 
obtained at mid-logarithmic or stationary growth phase, and the proteolytic activity 
toward azocasein was determined. Data represent the mean ±  SD of four 
experiments. 
 
Fig. 4. Growth of and protease production by vibrios in human serum. (A) The 
bacterial cells (2 x 107 CFU) inoculated into 2 ml of heat-treated 50 % human serum 
were incubated at 37 oC with shaking, and growth (A600) was measured periodically. 
(B) The cell-free serum sample was collected at the indicated times, and the activity of 
the extracellular protease was measured with azocasein. Data represent the mean ± 
SD of four experiments. 
 
Fig. 5. Growth of and protease production by vibrios in rabbit serum. (A) The 
bacterial cells (2 x 107 CFU) inoculated into 2 ml of heat-treated 50 % rabbit serum 
were incubated at 37 oC with shaking, and growth (A600) was measured periodically. 
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(B) The cell-free serum sample was collected at the indicated times, and the activity of 
the extracellular protease was measured with azocasein. Data represent the mean ± 
SD of four experiments. 
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